Back to top
more

Fortrea Holdings Inc. (FTRE)

(Delayed Data from NSDQ)

$18.31 USD

18.31
1,053,468

-0.08 (-0.44%)

Updated Aug 24, 2026 04:00 PM ET

After-Market: $18.30 -0.01 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Fortrea Holdings Inc. (FTRE) Moves 5.5% Higher: Will This Strength Last?

by Zacks Equity Research

Fortrea Holdings Inc. (FTRE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

Fortrea Holdings Inc. (FTRE) Q3 Earnings Lag Estimates

by Zacks Equity Research

Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of -25.00% and +9.21%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Rimmi Singhi headshot

5 Value Picks to Ride Out US-China Trade Rift & Government Shutdown

by Rimmi Singhi

Amid U.S.-China tensions and the U.S. government shutdown, five high-earnings-yield value stocks stand out for long-term investors.

Zacks Equity Research

Amarin (AMRN) Surges 12.5%: Is This an Indication of Further Gains?

by Zacks Equity Research

Amarin (AMRN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Fortrea Holdings Inc. (FTRE) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of +216.67% and +12.60%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AC Immune (ACIU) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

AC Immune (ACIU) delivered earnings and revenue surprises of -25.00% and -57.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Adaptive Biotechnologies (ADPT) Surges 12.5%: Is This an Indication of Further Gains?

by Zacks Equity Research

Adaptive Biotechnologies (ADPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Exelixis, Inc. (EXEL) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Exelixis (EXEL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

FTRE vs. ILMN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

FTRE vs. ILMN: Which Stock Is the Better Value Option?

Zacks Equity Research

Fortrea Holdings Inc. (FTRE) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of 128.57% and 6.79%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?